| Identification | Back Directory | [Name]
N-(4-fluorobenzyl)-5-isobutyl-2,2'-bithiazole-4-carboxamide | [CAS]
960527-22-4 | [Synonyms]
NZ-4
W 28 F
W-28-F
Isothiafludine
(NZ-4)
N-(4-fluorobenzyl)-5-isobutyl-2,2'-bithiazole-4-carboxamide | [Molecular Formula]
C18H18FN3OS2 | [MDL Number]
MFCD32710181 | [MOL File]
960527-22-4.mol | [Molecular Weight]
375.48 |
| Hazard Information | Back Directory | [Description]
Isothiafludine, also NZ-4 and W-28-F, is a HBV virus inhibitor that dramatically reduces the HBV DNA level in cells. During the hepatitis B virus (HBV) life cycle, nucleocapsid assembly is essential for HBV replication. Both RNA reverse transcription and DNA replication occur within the HBV nucleocapsid. HBV nucleocapsid is consisted of core protein (HBcAg), whose carboxy-terminal domain (CTD) contains an Arg-rich domain (ARD). The ARD of HBcAg does contribute to the encapsidation of pregenomic RNA (pgRNA). | [Uses]
Isothiafludine is an orally active non-nucleosidic anti-HBV compound. Isothiafludine inhibits hepatitis B virus replication by blocking pregenomic RNA encapsidation[1]. | [in vivo]
Isothiafludine (p.o., 25-100 mg/kg, for 15 days) inhibits DHBV DNA replication in a DHBV-infected duck model[1].
| Animal Model: | DHBV-infected duck model[2] | | Dosage: | 25-100 mg/kg | | Administration: | p.o., for 15 days | | Result: | Inhibited DHBV DNA in the sera on day 15. |
| [References]
[1] Yang L, et al. Isothiafludine, a novel non-nucleoside compound, inhibits hepatitis B virus replication through blocking pregenomic RNA encapsidation. Acta Pharmacol Sin. 2014 Mar;35(3):410-8. DOI:10.1038/aps.2013.175 |
|
| Company Name: |
Tcichem, Inc.
|
| Tel: |
13918644899 |
| Website: |
http://m.approvedhomemanagement.com/ShowSupplierProductsList19113/0.htm |
|